Antitumor Agents
DOI: 10.1002/anie.200602251
An Aptamer–Doxorubicin Physical Conjugate as
a Novel Targeted Drug-Delivery Platform**
Vaishali Bagalkot, Omid C. Farokhzad,* Robert Langer,
and Sangyong Jon*
The active targeting of drugs in a cell-, tissue-, or disease-
specific manner represents a potentially powerful technology
with widespread applications in medicine, including the
treatment of cancers. In a typical approach, a drug and a
ligand are complementarily functionalized to allow for
covalent or noncovalent (for example, biotin–streptavidin)
conjugation for targeted delivery. The resulting chemical
modifications of the drugs and/or the ligands may adversely
affect the safety and efficacy profile of the drugs and the
binding characteristics of the ligands, thereby resulting in less
efficacious drug–ligand conjugates. It would be desirable to
develop simple but effective targeted drug-delivery strategies
that do not require chemical modification of the drug or the
ligands.
Recently our group and other investigators have used
nucleic acid ligands or aptamers for therapeutic and diag-
nostic targeted-delivery applications.[1–6] Aptamers are struc-
tured single-stranded DNA or RNA molecules that can
specifically bind to small molecules,[7] peptides and proteins,[8]
and oligosaccharides[9] with high affinity and specificity.
Here we report a novel strategy for the targeted delivery
of doxorubicin (Dox) to cancer cells through the formation of
an aptamer–Dox physical conjugate. Dox is a well-known
anticancer drug which has shown efficacy against a range of
neoplasms, including acute lymphoblastic and myeloblastic
leukemias, malignant lymphomas, soft tissue and bone
sarcomas, and breast, ovarian, prostate, bladder, gastric, and
bronchogenic carcinomas. This widely used oncology drug is
also associated with dose-dependent cardiotoxicities, includ-
ing dilated cardiomyopathy and congestive heart failure,
which make the development of targeted Dox-delivery
systems of particular importance.[10] Dox is known to inter-
calate within the DNA strand due to the presence of flat
aromatic rings in this molecule. Other closely associated
drugs, such as donarubicin, have also been shown to be
intercalated into a double helix of DNA.[11] Since aptamers
are known to form tertiary conformations with short double-
stranded regions through intramolecular base pairing,[12] we
hypothesized that doxorubicin may intercalate into these
double-stranded regions and form a physical complex with
the aptamers through noncovalent intercalation, a process
requiring no modification of the drug or the aptamer
(Figure 1). We postulated that the resulting aptamer–Dox
physical conjugate may be used for the targeted delivery of
Dox by taking advantage of the aptamer6s binding specificity
to its target antigen. In this study, we have examined the
feasibility of this concept by using the A10 2’-fluoropyrimi-
dine RNA aptamer[13] that binds to the prostate-specific
membrane antigen (PSMA) with high affinity and specificity.
The two-dimensional structure of the A10 PSMA[13]
aptamer used herein was predicted by the M fold program.[14]
It is well known that the anthracycline class of drugs,
including Dox, have fluorescence properties that become
quenched after intercalation into DNA.[15,16] To examine
whether such intercalation also occurs within the RNA
aptamer, we carried out binding studies between the A10
PSMA aptamer and Dox. Fluorescence spectroscopy was
used to examine the binding of doxorubicin to the A10 PSMA
aptamer. Sequential decreases in the native fluorescence
spectrum of Dox were observed when a fixed concentration of
Figure 1. a) Physical-conjugate formation between an aptamer and a
model drug. b) 2D structure of the A10 PSMA aptamer as predicted by
M fold program and the chemical structure of doxorubicin.
[*] V. Bagalkot, Prof. Dr. S. Jon
Department of Life Science
Gwangju Institute of Science and Technology
1 Oryoung-dong, Buk-gu, Gwangju 500712 (South Korea)
Fax: (+82)62-970-2504
E-mail: syjon@gist.ac.kr
V. Bagalkot, Prof. Dr. O. C. Farokhzad
Department of Anaesthesiology
Brigham and Women’s Hospital and Harvard Medical School
75 Francis Street, Boston, MA 02115 (USA)
Fax: (+1)617-730-2801
E-mail: ofarokhzad@partners.org
Prof. Dr. R. Langer
Department of Chemical Engineering
Massachusetts Institute of Technology
E25-342, 45 Carleton Street, Cambridge, MA 02139 (USA)
[**] This work was supported by Korea Science and Technology
Foundation grant R01-2006-000-10818-0 (S.J. and V.B.) and USA
National Institutes of Health grants CA119349 (R.L., O.F., and V.B.)
and EB003647 (O.F.). We also thank Prof. C. S. Park for helpful
discussions. This work is dedicated to the families of patients with
cancer.
Supporting information for this article is available on the WWW
under http://www.angewandte.org or from the author.
Angewandte
Chemie
8149Angew. Chem. Int. Ed. 2006, 45, 8149 –8152 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Dox was incubated with an increasing molar ratio of the A10
PSMA aptamer, results consistent with the intercalation of
Dox within the A10 PSMA aptamer (Figure 2). Dox is known
to preferentially bind to double-stranded 5’-GC-3’ or 5’-CG-3’
sequences,[17, 18] and evaluation of the predicted A10 aptamer
secondary structure reveals one possible site for Dox
intercalation, as marked by an asterisk in Figure 1b. The
incubation of Dox with the A10 aptamer results in maximal
quenching of the Dox fluorescence at approximately 1:1.2
molar equivalence of Dox to aptamer, a result suggesting that
Dox makes a physical conjugate with the A10 aptamer by
intercalating into its predicted CG sequence (Figure 2). The
inset of Figure 2 shows a Hill plot of fluorescence quenching
as a function of increasing aptamer concentration. The
dissociation constant (Kd= 600 nm) of the aptamer–Dox
physical conjugate was derived from this figure and suggests
a spontaneously formed stable physical conjugate. The
stability of the aptamer–Dox conjugate was further confirmed
by high-pressure liquid chromatography (HPLC) where the
conjugate peak appeared at a different elution time from
those of the native aptamer and Dox (data not shown). A
study of the release of Dox from the aptamer–Dox physical
conjugate over time was conducted by using a dialysis tube
(see Figure S1 in the Supporting Information). Upon dialysis,
more than 80% Dox release was observed in 6 h with zero-
order kinetics, which suggests that the Dox molecule is
released from the conjugate beyond the concentration of its
dissociation constant by simple diffusion.
To evaluate the feasibility of the aptamer–Dox physical
conjugate as a targeted drug-delivery platform, we performed
in vitro binding and uptake studies with the LNCaP prostate
epithelial cells which express the target PSMA protein on
their plasma membrane. We used the PC3 prostate epithelial
cells which do not express any detectable level of the PSMA
protein as a negative control (Figure 3). Our confocal laser
scanning microscopy data demonstrate that while free Dox
readily diffuses through the plasma membrane of LNCaP and
PC3 cells with equal efficiency (Figure 3a and b), there is a
remarkable specificity in the uptake of the aptamer–Dox
conjugate by LNCaP but not PC3 cells (Figure 3c and d), as
marked by strong nuclear fluorescence that is consistent with
the intercalation of Dox within the genomic DNA.
The mechanisms of uptake of the aptamer–Dox physical
conjugate and the free Dox by LNCaP cells appear distinct.[19]
Unlike free Dox, which exclusively stains the nuclei, the
aptamer–Dox conjugate demonstrates both nuclear and
cytosolic staining, with the latter predominately in the form
of punctuate granules that are consistent with compartmen-
talization of the Dox within endosomes (Figure 3c). This
pattern of cytosolic staining is consistent with receptor-
mediated endocytic uptake of the aptamer–Dox physical
conjugate, which results after binding of the conjugate to the
PSMA protein on the LNCaP plasma membrane. The
aptamer–Dox physical conjugate failed to produce any
cytosolic staining of the PC3 cells, a result consistent with
the lack of PSMA protein expression in these cells (Fig-
ure 3d). The weak fluorescence staining of the PC3 nuclei
after incubating with the aptamer–Dox conjugate is likely
attributable to a small amount of free Dox that may be
present in the media bathing the cells. Indeed, the LNCaP-
and PC3-binding data suggest that the majority of Dox
remains in the form of a complex with the aptamer, thereby
demonstrating the stability of the aptamer–Dox physical
conjugate over time in the culture media. Furthermore, the
data demonstrate the ability of an aptamer to retain its
binding characteristics while the Dox is intercalated within it,
so allowing the targeted delivery of Dox to the cells that
express the aptamer target. We next compared the binding
characteristics of an equimolar concentration of the aptamer–
Dox physical conjugate to the free aptamer in LNCaP-
binding assays.[20] By using quantitative PCR amplification of
the LNCaP-bound aptamers, about 84% of the binding ability
Figure 2. Fluorescence spectra of doxorubicin solution (1.5 mm) with
increasing molar ratios of the aptamer (from top to bottom: 0, 0.01,
0.03, 0.1, 0.3, 0.5, 1, 3, 5, 7, and 10 equiv). Inset: A Hill plot for the
aptamer titration (Kd=0.6 mm ; 0.52 equiv of the aptamer).
Figure 3. Confocal laser scanning microscopy images (superimposed
images of fluorescence and transmittance) of LNCaP (a and c) and
PC3 (b and d) cells after treatments of 1.5 mm free doxorubicin (a and
b) and of 1.5 mm aptamer–Dox physical conjugate (c and d) for 2 h.
Scale bars: 20 mm.
Communications
8150 www.angewandte.org 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2006, 45, 8149 –8152
of the A10 aptamer was shown to be retained by the aptamer–
Dox physical conjugate (see Figure S2 in the Supporting
Information). This result also demonstrates the ability of an
aptamer to retain its binding characteristics while the Dox is
intercalated within it, thereby allowing the targeted delivery
of Dox to the cells that express the aptamer target.
The targeting specificity of the aptamer–Dox physical
conjugate was next quantified by flow cytometry experiments
(Figure 4). The data demonstrate near-identical staining of
LNCaP and PC3 cells after treatment of these cells with free
Dox (Figure 4a and b). However, when LNCaP and PC3 cells
were incubated with the aptamer–Dox physical conjugate,
there was a significant enhancement in the fluorescence signal
from LNCaP cells as compared to that from PC3 cells
(FL2 log intensity for LNCaP was 123� 4.66 versus 35� 1.79
for PC3; mean� standard error (SE), number of samples
(N)= 4), which validates the targeting specificity of the
aptamer–Dox physical conjugate (Figure 4c). Taken together,
our microscopy and flow cytometry data demonstrate the
proof of concept for the feasibility of the aptamer–Dox
physical conjugate to serve as a novel drug-delivery platform
for a variety of applications in oncology.
We next examined whether the targeted delivery of the
aptamer–Dox physical conjugate to LNCaP cells results in
enhanced cellular cytotoxicity[21] compared to that in PC3
control cells. We first demonstrated in escalating-dose studies
that the cytotoxicity of free Dox to LNCaP and PC3 cells is
equipotent (data not shown). At a dose where the cytotoxicity
of free Dox had reached a plateau near its maximum, we
compared the cytotoxic efficacy of free Dox (5 mm) to that of
the aptamer–Dox physical conjugate (5 mm), as well as that of
free aptamer without Dox, on LNCaP and PC3 cells by MTT
assay. The data demonstrate that while the cytotoxicity of free
Dox is equipotent against LNCaP and PC3 cells, the
cytotoxicity of the aptamer–Dox conjugate is significantly
enhanced against the targeted LNCaP cells as compared to
the nontargeted PC3 cells (cellular viability: 52.8%� 1.73
LNCaP versus 75.2%� 1.19 PC3; mean�SE, N= 5; proba-
bility value (p)< 0.005; Figure 5). Interestingly, the data
demonstrate a near-equipotent cytotoxicity of the aptamer–
Dox physical conjugate to the LNCaP cells as compared to
that of free Dox. The free aptamer without Dox had no
inherent cytotoxicity to LNCaP or PC3 cells (Figure 5). Our
data suggest that, after endocytic uptake, the aptamer–Dox
physical conjugate releases the Dox molecules inside the
LNCaP cells, possibly due to the aptamer–Dox dissociation
constant favoring the release of Dox because of the relatively
negligible concentrations of Dox inside the cells. Alterna-
tively, the release of Dox from the aptamer–Dox physical
conjugate may occur through gradual degradation of the
aptamer by endonucleases in the lysosomes after cellular
uptake. We postulate that a combination of these factors may
contribute to the observed findings. In contrast to the
dramatic cytotoxic effects of the aptamer–Dox complex to
the LNCaP cells, the cytotoxicity of this physical-conjugate
system to PC3 cells was significantly less pronounced, a result
consistent with the lack of PSMA expression in PC3 cells.
In conclusion, by exploiting the ability of anthracycline
drugs to intercalate between bases of polynucleotides, a novel
physical conjugate was made between the anticancer drug
Dox and the A10 RNA aptamer that binds to the PSMA
protein on the surface of prostate cancer cells. The stability
and efficacy of this conjugate to serve as a novel drug-delivery
platform was further demonstrated in vitro. Our data suggest
that the aptamer–Dox physical conjugate is stable in the cell-
culture medium and could differentially and with high
Figure 4. Flow cytometry histogram profiles of LNCaP (dotted line)
and PC3 (solid line) cells obtained after treatments with a) nothing,
b) 1.5 mm free doxorubicin, and c) 1.5 mm aptamer–Dox physical con-
jugate. FL2 log= fluorescence intensity of FL2 sensor (band pass filter,
575 nm).
Angewandte
Chemie
8151Angew. Chem. Int. Ed. 2006, 45, 8149 –8152 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
efficiency target the PSMA-expressing LNCaP cells. The
specificity of the system was further demonstrated by the lack
of targeting of the PSMA-negative PC3 cells. We expect that
the small size of the aptamer–Dox physical-conjugate system
(� 18 kD) as compared to that of similar antibody-based
immunoconjugates (� 150 kD) may facilitate the rapid vas-
cular extravasation and intratumoral penetration of the
former, thereby making it a therapeutically effective drug-
delivery system for in vivo applications.[22] The much larger
nanoparticle drug-delivery systems compensate for their size
disadvantage through their capacity to release a large payload
of drug in a controlled manner, a property that makes each
ligand–target biorecognition a potentially relevant therapeu-
tic event. Each of these systems may contribute in a unique
way to our arsenal of cancer-therapy options in the future.[23]
Furthermore, these systems may be combined such that a
targeted nanoparticle–aptamer bioconjugate system may
deliver distinct drugs through encapsulation within the nano-
particles and through intercalation within the aptamers, with
the result of a temporally distinct release of two or more drugs
for combination chemotherapy.[1–3] We anticipate that the
aforementioned aptamer–drug platform technology based on
the intercalation of anthracyclines within the bases of
aptamers may be utilized in distinct ways to develop novel
targeted therapeutic modalities for more effective cancer
chemotherapy. In the next phase of our studies, we will be
evaluating the in vivo efficacy of the aptamer–Dox physical
conjugate in animal models of cancer.
Received: June 6, 2006
Revised: September 18, 2006
Published online: November 13, 2006
.Keywords: antitumor agents · aptamers · conjugation ·
drug delivery · targeted therapy
[1] O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W.
Kantoff, J. P. Richie, R. Langer, Proc. Natl. Acad. Sci. USA 2006,
103, 6315.
[2] O. C. Farokhzad, S. Jon, A. Khademhosseini, T. N. Tran, D. A.
Lavan, R. Langer, Cancer Res. 2004, 64, 7668.
[3] O. C. Farokhzad, J. M. Karp, R. Langer, Expert Opin. Drug
Delivery 2006, 3, 311.
[4] B. J. Hicke, A. W. Stephens, T. Gould, Y. F. Chang, C. K. Lynott,
J. Heil, S. Borkowski, C. S. Hilger, G. Cook, S. Warren, P. G.
Schmidt, J. Nucl. Med. 2006, 47, 668.
[5] C. Pestourie, B. Tavitian, F. Duconge, Biochimie 2005, 87, 921.
[6] a) T. C. Chu, J. W. Marks, III, L. A. Lavery, S. Faulkner, M. G.
Rosenblum, A. D. Ellington, M. Levy, Cancer Res. 2006, 66,
5989; b) J. O. McNamara, 2nd, E. R. Andrechek, Y. Wang,
K. D. Viles, R. E. Rempel, E. Gilboa, B. A. Sullenger, P. H.
Giangrande, Nat. Biotechnol. 2006, 24, 1005.
[7] J. Flinders, S. C. DeFina, D. M. Brackett, C. Baugh, C. Wilson, T.
Dieckmann, ChemBioChem 2004, 5, 62.
[8] D. J. Patel, A. K. Suri, F. Jiang, L. Jiang, P. Fan, R. A. Kumar, S.
Nonin, J. Mol. Biol. 1997, 272, 645.
[9] S. Jeong, T. Eom, S. Kim, S. Lee, J. Yu, Biochem. Biophys. Res.
Commun. 2001, 281, 237.
[10] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni,
Pharmacol. Rev. 2004, 56, 185.
[11] P. Fan, A. K. Suri, R. Fiala, D. Live, D. J. Patel, J. Mol. Biol. 1996,
258, 480.
[12] D. Sussman, J. C. Nix, C. Wilson, Nat. Struct. Biol. 2000, 7, 53.
[13] S. E. Lupold, B. J. Hicke, Y. Lin, D. S. Coffey, Cancer Res. 2002,
62, 4029.
[14] M. Zuker, Nucleic Acids Res. 2003, 31, 3406.
[15] H. T. Haj, M. Salerno, W. Priebe, H. Kozlowski, A. Garnier-
Suillerot, Chem. Biol. Interact. 2003, 145, 349..
[16] L. Valentini, V. Nicolella, E. Vannini, M. Menozzi, S. Penco, F.
Arcamone, Farmaco [Sci] 1985, 40, 377.
[17] J. B. Chaires, J. E. Herrera, M. J. Waring, Biochemistry 1990, 29,
6145.
[18] C. A. Frederick, L. D. Williams, G. Ughetto, G. A. van der
Marel, J. H. van Boom, A. Rich, A. H.Wang,Biochemistry 1990,
29, 2538.
[19] H. S. Yoo, K. H. Lee, J. E. Oh, T. G. Park, J. Controlled Release
2000, 68, 419.
[20] T. C. Chu, F. Shieh, L. A. Lavery, M. Levy, R. Richards-Kortum,
B. A. Korgel, A. D. Ellington, Biosens. Bioelectron. 2006, 21,
1859.
[21] S. Akaishi, M. Kobari, K. Takeda, S. Matsuno, Tohoku J. Exp.
Med. 1995, 175, 29.
[22] A. M. Wu, P. D. Senter, Nat. Biotechnol. 2005, 23, 1137.
[23] S. S. Feng, Expert Rev. Med. Devices 2004, 1, 115.
Figure 5. Growth-inhibition assay (MTT) results for prostrate cancer
cell lines LNCaP and PC3 after 2 h of incubation with free doxorubicin
(5 mm) and the physical conjugate (5 mm) and 24 h of subsequent
incubation. * indicates the LNCaP result that is significantly different
from that with PC3 cells (p<0.005, N=5).
Communications
8152 www.angewandte.org 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2006, 45, 8149 –8152
本文档为【An Aptamer-Doxorubicin Physical Conjugate as a Novel Targeted Drug-Delivery Platform】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。